128 related articles for article (PubMed ID: 7939764)
1. Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (Taxol).
Beijnen JH; Huizing MT; ten Bokkel Huinink WW; Veenhof CH; Vermorken JB; Giaccone G; Pinedo HM
Semin Oncol; 1994 Oct; 21(5 Suppl 8):53-62. PubMed ID: 7939764
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel pharmacokinetics and pharmacodynamics.
Kearns CM; Gianni L; Egorin MJ
Semin Oncol; 1995 Jun; 22(3 Suppl 6):16-23. PubMed ID: 7597430
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of paclitaxel administered as a 1-hour infusion: toxicity and pharmacokinetics.
Maier-Lenz H; Hauns B; Haering B; Koetting J; Mross K; Unger C; Bauknecht T; du Bois A; Meerpohl HG; Hollaender N; Diergarten K
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-16-S19-19. PubMed ID: 9427259
[TBL] [Abstract][Full Text] [Related]
4. Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function.
Panday VR; Huizing MT; Willemse PH; De Graeff A; ten Bokkel Huinink WW; Vermorken JB; Beijnen JH
Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-34-S11-38. PubMed ID: 9314297
[TBL] [Abstract][Full Text] [Related]
5. [Paclitaxel (Taxol)].
Hájek R
Cas Lek Cesk; 1996 Jun; 135(12):393-6. PubMed ID: 8706079
[TBL] [Abstract][Full Text] [Related]
6. A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel.
Calvert AH
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-85-S2-90. PubMed ID: 9045345
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
Langer CJ; Millenson M; Rosvold E; Litwin S; McAleer CA; Bonjo CA; Ozols R
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel and carboplatin in early phase studies: Roswell Park Cancer Institute experience in the subset of patients with lung cancer.
Creaven PJ; Raghavan D; Pendyala L; Loewen G; Kindler HL; Berghorn EJ
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-138-S12-143. PubMed ID: 9331139
[TBL] [Abstract][Full Text] [Related]
9. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
Sparreboom A; van Tellingen O; Nooijen WJ; Beijnen JH
Cancer Res; 1996 May; 56(9):2112-5. PubMed ID: 8616858
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel (3-hour infusion) followed by carboplatin (24 hours after paclitaxel): a phase II study in advanced non-small cell lung cancer.
Roychowdhury DF; Desai P; Zhu YW
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-37-S12-40. PubMed ID: 9331119
[TBL] [Abstract][Full Text] [Related]
11. High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial.
Longnecker SM; Donehower RC; Cates AE; Chen TL; Brundrett RB; Grochow LB; Ettinger DS; Colvin M
Cancer Treat Rep; 1987 Jan; 71(1):53-9. PubMed ID: 2878719
[TBL] [Abstract][Full Text] [Related]
12. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer.
Dombernowsky P; Gehl J; Boesgaard M; Jensen TP; Jensen BV
Semin Oncol; 1996 Feb; 23(1 Suppl 1):13-8. PubMed ID: 8629030
[TBL] [Abstract][Full Text] [Related]
15. Treatment of metastatic breast cancer with paclitaxel and doxorubicin.
Dombernowsky P; Gehl J; Boesgaard M; Jensen TP; Jensen BW; Ejlertsen B
Semin Oncol; 1995 Dec; 22(6 Suppl 15):13-7. PubMed ID: 8643964
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion.
Ohtsu T; Sasaki Y; Tamura T; Miyata Y; Nakanomyo H; Nishiwaki Y; Saijo N
Clin Cancer Res; 1995 Jun; 1(6):599-606. PubMed ID: 9816021
[TBL] [Abstract][Full Text] [Related]
17. Carboplatin plus paclitaxel in the first-line treatment of advanced ovarian cancer: preliminary results of a phase I study.
Lhommé C; Kerbrat P; Lejeune C; Guastalla JP; Fumoleau P; Goupil A; Héron JF; Cassin MA; Pruvot I; Soares JA; Chazard M
Semin Oncol; 1996 Oct; 23(5 Suppl 12):48-54. PubMed ID: 8941410
[TBL] [Abstract][Full Text] [Related]
18. Early phase studies with paclitaxel/low-dose carboplatin in patients with solid tumors.
Creaven PJ; Raghavan D; Perez RP; Pendyala L; Berghorn EJ; Loewen G; Meropol NJ
Semin Oncol; 1996 Dec; 23(6 Suppl 16):26-31. PubMed ID: 9007117
[TBL] [Abstract][Full Text] [Related]
19. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors.
Sonnichsen DS; Hurwitz CA; Pratt CB; Shuster JJ; Relling MV
J Clin Oncol; 1994 Mar; 12(3):532-8. PubMed ID: 7907130
[TBL] [Abstract][Full Text] [Related]
20. Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy.
Weiner LM; Colarusso P; Goldberg M; Dresler C; Coia LR
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-93-S19-95. PubMed ID: 9427276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
